Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, and its treatment landscape is continually evolving. Central to the growth and survival of the majority of prostate cancers is their reliance on androgens, the primary male sex hormones. Standard therapies for advanced prostate cancer often include androgen deprivation, either through reducing androgen levels or blocking androgen receptor activity. However, despite initial success, many patients face tumor recurrence due to the development of therapeutic resistance. The molecular mechanisms underpinning this resistance have been a subject of intense investigation, as understanding them could pave the way for novel treatment strategies.
A groundbreaking study recently published in EMBO Molecular Medicine has shed light on a pivotal pathway that allows prostate tumors to circumvent the blockade of androgen signaling. This research, conducted by an international consortium led by Israel Prize laureate Prof. Yosef Yarden at the Weizmann Institute of Science, identifies a genetic alteration that enables tumors to exploit cortisol — a glucocorticoid steroid hormone — to fuel their growth when androgen pathways are inhibited. This discovery not only deepens our comprehension of prostate cancer biology but also suggests potential new therapeutic avenues for patients harboring this genetic alteration.
The genetic alteration in question involves a fusion of two genes, a mutation present in approximately fifty percent of prostate cancer cases. This gene fusion encodes a unique protein that interacts directly with the glucocorticoid receptor (GR), a nuclear hormone receptor activated by cortisol. Under normal physiological conditions, androgen receptor signaling represses this pathway. However, in the context of androgen deprivation therapy, this suppression is lifted, and the tumors pivot to a cortisol-driven growth mechanism. This cellular switch effectively allows the cancer to evade the effects of androgen-targeted therapies — a hallmark of therapeutic resistance.
To elucidate the biological implications of this gene fusion, Dr. Arunachalam Sekar and colleagues employed sophisticated mouse models engineered to recapitulate human prostate cancer bearing the gene fusion. These models demonstrated that simultaneous inhibition of both androgen receptor signaling and glucocorticoid receptor activity led to significantly improved tumor suppression compared to targeting androgen signaling alone. Such findings underscore the potential of combination therapies to delay or overcome resistance in this subset of prostate cancer patients.
The mechanistic insights from the study reveal that the fusion protein serves as a scaffold, recruiting the glucocorticoid receptor to specific genomic loci, thereby driving transcriptional programs that promote cell proliferation and survival. This gene regulatory network activated by cortisol is largely dormant in tumors without the gene fusion but becomes a potent alternative growth axis when androgen receptor activity is compromised. The team’s molecular profiling and chromatin immunoprecipitation experiments delineated the pathways engaged by this fusion protein-GR complex, highlighting targets that could be disrupted pharmacologically.
Importantly, the clinical ramifications extend beyond the design of new therapies. Glucocorticoids are frequently administered to manage side effects or complications in cancer patients, including those with advanced prostate cancer. This practice, however, may inadvertently accelerate tumor progression in patients with the fusion-positive tumors by activating the glucocorticoid receptor pathway. Prof. Yarden emphasizes the urgent need for caution in prescribing steroid medications in this context and stresses identifying patients with the genetic fusion to tailor safer and more effective therapeutic regimens.
The study’s translational potential is bolstered by the recent FDA approval of a glucocorticoid receptor antagonist initially developed for ovarian cancer. When tested in the prostate cancer mouse models, this antagonist effectively inhibited cortisol receptor-mediated signaling and, in combination with anti-androgens, extended survival and reduced tumor growth markedly. These preclinical results justify further clinical investigations to evaluate whether such combination therapies could be beneficial in patients harboring the gene fusion.
A significant strength of this study is the integration of human patient data with experimental models. Collaborations with the National Cancer Institute enabled the research team to validate their findings in clinical specimens, confirming the prevalence of the gene fusion in a sizable fraction of prostate cancer biopsies. This translational approach ensures that the molecular insights are grounded in clinical reality and heightens the potential for impact on patient care.
This discovery reframes our understanding of steroid hormone biology in cancer progression and challenges existing paradigms that consider androgen deprivation therapy as a stand-alone treatment for hormone-sensitive prostate tumors. The identification of an alternative steroid hormone receptor pathway mediated by cortisol illustrates the plasticity of cancer cells in co-opting physiological signaling circuits to survive therapeutic pressures. This concept may also have implications for resistance mechanisms in other hormone-driven cancers.
Future research efforts will likely focus on refining diagnostic tools to detect this gene fusion and monitoring cortisol receptor activity in patients. Liquid biopsy approaches or molecular imaging techniques could provide minimally invasive methods to stratify patients and guide personalized therapy. Moreover, dissecting the downstream effectors of the fusion protein-GR complex could unveil additional therapeutic targets to disrupt tumor growth resilience.
In sum, the elucidation of cortisol’s role in driving prostate cancer progression via a gene fusion-mediated mechanism opens promising new avenues for intervention. By combining anti-androgen therapy with glucocorticoid receptor inhibition, there is potential to achieve more durable responses and mitigate the emergence of resistance. This paradigm shift not only offers hope for improved management of advanced prostate cancer but also highlights the intricate interplay between steroid hormones and cancer biology.
Prof. Yosef Yarden, who leads the Dwek Institute for Cancer Therapy Research and holds the Harold and Zelda Goldenberg Professorial Chair in Molecular Cell Biology, underscores the broader significance of these findings. Beyond prostate cancer, understanding hormone receptor crosstalk and pathway switching could inform therapeutic strategies across diverse malignancies. This landmark study exemplifies how molecular science coupled with translational research can illuminate cancer vulnerabilities and ultimately impact patient outcomes.
Subject of Research: Molecular mechanisms of hormone-driven resistance in prostate cancer and therapeutic strategies targeting androgen and glucocorticoid receptor signaling.
Article Title: Gene Fusion-Driven Cortisol Signaling: A Novel Mechanism of Androgen Therapy Resistance in Prostate Cancer.
News Publication Date: 2026.
Web References:
References:
The article is based on a study published in EMBO Molecular Medicine with collaborative data from the National Cancer Institute.
Keywords: Prostate cancer, androgen receptor, glucocorticoid receptor, cortisol, gene fusion, therapeutic resistance, hormone therapy, combination therapy, steroid hormones, molecular oncology, cancer biology, drug resistance.
